Apomorphine and levodopa infusion therapies for advanced Parkinson's disease.

about

Pharmacological Insights into the Use of Apomorphine in Parkinson's Disease: Clinical Relevance.The Many Faces of Apomorphine: Lessons from the Past and Challenges for the Future.

P2860

Q47868277-D927772F-0837-4FFA-B1EC-FCB5885CB43C Q52316533-DF046A87-8CA3-493E-8E70-DD833FEF650D

P2860

Apomorphine and levodopa infusion therapies for advanced Parkinson's disease.

Item

http://www.wikidata.org/entity/Q38215506

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Apomorphine and levodopa infusion therapies for advanced Parkinson's disease.

@en

type

Item

label

Apomorphine and levodopa infusion therapies for advanced Parkinson's disease.

@en

altLabel

Apomorphine and Levodopa Infusion Therapies for Advanced Parkinson’s Disease

@en

prefLabel

Apomorphine and levodopa infusion therapies for advanced Parkinson's disease.

@en

P1476

Apomorphine and levodopa infusion therapies for advanced Parkinson's disease.

@en

P2860

Dopamine agonist therapy in early Parkinson's disease

Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment

Treatment interventions for Parkinson's disease: an evidence based assessment

On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients

Intravenous apomorphine therapy in Parkinson's disease: clinical and pharmacokinetic observations.

Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial.

Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA.

Levodopa in the treatment of Parkinson's disease: a consensus meeting.

Levodopa prolongs life expectancy and is non-toxic to substantia nigra.

[Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system].

P304

4-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.14802/JMD.09002

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Angelo Antonini

P577

2009-04-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262694689

http://www.w3.org/2001/XMLSchema#string

P698

24868344

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

levodopa

P932

4027699

http://www.w3.org/2001/XMLSchema#string

Apomorphine and levodopa infusion therapies for advanced Parkinson's disease.

about

P2860

P2860

Apomorphine and levodopa infusion therapies for advanced Parkinson's disease.

description

name

type

label

altLabel

prefLabel

P1433

P1476

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P932